Favipiravir, umifenovir and camostat mesylate: a comparative study against SARS-CoV-2
M. A. Unal, O. Besbinar, H. Nazir, G. Y. Summak, F. Bayrakdar, L. G. Delogu, T. Taskin, S. A. Ozkan, K. C. Akcali, A. Yilmazer
This study compares the antiviral effects of favipiravir, umifenovir, and camostat mesylate against SARS-CoV-2 using in silico and in vitro methods, finding that combination treatments are more effective than single drugs.
bioRxiv · Jan 11, 2022 · PreprintPharmacology & Toxicology